m-Chlorophenylpiperazine as a probe of serotonin function

m-Chlorophenylpiperazine (mCPP) is the most extensively used probe of serotonin function in psychiatry. This article reviews its in vitro and in vivo properties in animals, normal human subjects, and psychiatric patients. mCPP is a safe, reliable, direct 5-hydroxytryptamine (5HT) agonist, which may be used to evaluate 5HT receptor sensitivity. It causes a consistent, dose-dependent elevation of ACTH, cortisol, and prolactin levels in both animals and humans, as well as increased body temperature in man. It also causes a variety of behavioral effects, depending on the population studied. These effects are probably 5HT receptor-related, although specific 5HT receptor subtype mechanisms have not yet been established. mCPP may be considered an important addition to armamentarium of 5HT receptor probes, which is especially useful until more selective 5HT receptor agonists have been tested.

[1]  D. Murphy,et al.  The serotonin agonist, M-chlorophenyl-piperazine, markedly increases levels of plasma catecholamines in the conscious rat , 1988, Neuropharmacology.

[2]  P. Conn,et al.  Relative efficacies of piperazines at the phosphoinositide hydrolysis-linked serotonergic (5-HT-2 and 5-HT-1c) receptors. , 1987, The Journal of pharmacology and experimental therapeutics.

[3]  R. Kahn,et al.  The MCPP challenge test in schizophrenia: Hormonal and behavioral responses , 1991, Biological Psychiatry.

[4]  R. Kahn,et al.  Serotonin receptor sensitivity in major depression , 1990, Biological Psychiatry.

[5]  D. Hoyer.  Functional correlates of serotonin 5-HT1 recognition sites. , 1988, Journal of receptor research.

[6]  A. Quattrone,et al.  Pharmacological evidence of supersensitivity of central serotonergic receptors involved in the control of prolactin secretion. , 1981, European journal of pharmacology.

[7]  D. Murphy,et al.  Clorgyline treatment differentially affects m-chlorophenylpiperazine-induced neuroendocrine changes. , 1988, European journal of pharmacology.

[8]  J. Tuomisto,et al.  Neurotransmitter regulation of anterior pituitary hormones. , 1985, Pharmacological reviews.

[9]  J. Williams,et al.  Serotonin‐mediated inhibitory postsynaptic potential in guinea‐pig prepositus hypoglossi and feedback inhibition by serotonin. , 1990, The Journal of physiology.

[10]  Gavin Kilpatrick,et al.  Identification and distribution of 5-HT3 receptors in rat brain using radioligand binding , 1987, Nature.

[11]  R. Kahn,et al.  Pituitary hormone responses to meta-chlorophenylpiperazine in panic disorder and healthy control subjects , 1991, Psychiatry Research.

[12]  S. Garattini,et al.  Interactions between putative neurotransmitters in the brain , 1978 .

[13]  C. Bendotti,et al.  Hyper- and hyposensitivity of central serotonin receptors: [3H]serotonin binding and functional studies in the rat , 1980, Brain Research.

[14]  R. Kahn,et al.  Serotonin and anxiety revisited , 1988, Biological Psychiatry.

[15]  R. Kahn,et al.  Hypersensitivity to m-chlorophenylpiperazine in a subject with subclinical panic attacks , 1990, Biological Psychiatry.

[16]  E. Edwards,et al.  5-HT1A and 5-HT1B agonists play a differential role on the respiratory frequency in rats. , 1990, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

[17]  D. Murphy,et al.  Hyperresponsivity to the serotonin agonist m-chlorophenylpiperazine in Alzheimer's disease. A controlled study. , 1989, Archives of general psychiatry.

[18]  S. Stahl,et al.  Relationship of increased food intake and plasma ACTH levels to 5-HT1A receptor activation in rats , 1988, Psychoneuroendocrinology.

[19]  W. Cahn,et al.  Effects of serotonin antagonists on m-chlorophenylpiperazine-mediated responses in normal subjects , 1990, Psychiatry Research.

[20]  D. Murphy,et al.  Effects of fenfluramine, m-chlorophenylpiperazine, and other serotonin-related agonists and antagonists on penile erections in nonhuman primates. , 1988, Life sciences.

[21]  M. Williams,et al.  Serotonin-releasing effects of substituted piperazines in vitro. , 1984, Biochemical pharmacology.

[22]  D. Murphy,et al.  Ethanollike properties of the serotonergic partial agonist m-chlorophenylpiperazine in chronic alcoholic patients. , 1991, Archives of general psychiatry.

[23]  D. Murphy,et al.  Induction of migrainelike headaches by the serotonin agonist m‐chlorophenylpiperazine , 1988, Clinical pharmacology and therapeutics.

[24]  Jeffrey K. Yao,et al.  Serotonergic responsivity and behavioral dimensions in antisocial personality disorder with substance abuse , 1990, Biological Psychiatry.

[25]  L. Descarries,et al.  Description of an indolaminergic cell component in the cat locus coeruleus: A fluorescence histochemical and radioautographic study , 1979, Brain Research.

[26]  I. Lucki,et al.  Development of selective tolerance to the serotonin behavioral syndrome and suppression of locomotor activity after repeated administration of either 5-MeODMT or mCPP. , 1985, Life sciences.

[27]  R. Fuller,et al.  Disposition and pharmacological effects of m-Chlorophenylpiperazine in rats , 1981, Neuropharmacology.

[28]  S. Peroutka,et al.  1-(m-Chlorophenyl)piperazine (mCPP) interactions with neurotransmitter receptors in the human brain , 1989, Biological Psychiatry.

[29]  D. Murphy,et al.  A preliminary study of the effects of intravenous m-chlorophenylpiperazine, a serotonin agonist, in elderly subjects , 1989, Biological Psychiatry.

[30]  R. Suckow,et al.  Trazodone and m-chlorophenylpiperazine Concentration in brain and receptor activity in regions in the brain associated with anxiety , 1985, Neuropharmacology.

[31]  S. Woods,et al.  Serotonin function in obsessive-compulsive disorder. A comparison of the effects of tryptophan and m-chlorophenylpiperazine in patients and healthy subjects. , 1988, Archives of general psychiatry.

[32]  M. Melzacka,et al.  Effect of dosage and route of administration of trazodone on cerebral concentration of 1-m-chlorophenylpiperazine in rats. Kinetics of trazodone biotransformation in rats. , 1983, Polish journal of pharmacology and pharmacy.

[33]  D. Murphy,et al.  Long‐term imipramine treatment enhances locomotor and food intake suppressant effects of m‐chlorophenylpiperazine in rats , 1987, British journal of pharmacology.

[34]  G. Kennett,et al.  Evidence that mCPP may have behavioural effects mediated by central 5‐HT1C receptors , 1988, British journal of pharmacology.

[35]  D. Hoyer,et al.  Molecular pharmacology of 5-HT1 and 5-HT2 recognition sites in rat and pig brain membranes: radioligand binding studies with [3H]5-HT, [3H]8-OH-DPAT, (-)[125I]iodocyanopindolol, [3H]mesulergine and [3H]ketanserin. , 1985, European journal of pharmacology.

[36]  D. Murphy,et al.  Metergoline blocks the behavioral and neuroendocrine effects of orally administered m-chlorophenylpiperazine in patients with obsessive-compulsive disorder , 1991, Biological Psychiatry.

[37]  L. Descarries,et al.  Serotonin nerve terminals in the locus coeruleus of adult rat: A radioautographic study , 1978, Brain Research.

[38]  M. Segal.  Serotonergic innervation of the locus coeruleus from the dorsal raphe and its action on responses to noxious stimuli. , 1979, The Journal of physiology.

[39]  D. Murphy,et al.  A preliminary study of the effects of nighttime administration of the serotonin agonist, m-CPP, on sleep architecture and behavior in healthy volunteers , 1991, Biological Psychiatry.

[40]  J. Gerlach,et al.  Behavioral aspects of serotonin-dopamine interaction in the monkey. , 1985, European journal of pharmacology.

[41]  S. Garattini,et al.  (—)‐m‐Chlorophenyl‐piperazine, a central 5‐hydroxytryptamine agonist, is a metabolite of trazodone , 1981, The Journal of pharmacy and pharmacology.

[42]  A. Dray,et al.  Evidence for the existence of a raphe projection to the substantia nigra in rat , 1976, Brain Research.

[43]  D. Hoyer,et al.  Competitive interaction of agonists and antagonists with 5-HT3 recognition sites in membranes of neuroblastoma cells labelled with [3H]ICS 205-930. , 1989, Journal of receptor research.

[44]  T. Insel,et al.  Serotonergic responsivity in obsessive-compulsive disorder. Effects of chronic clomipramine treatment. , 1988, Archives of general psychiatry.

[45]  T. Insel,et al.  Neuroendocrine and behavioral effects of m-chlorophenylpiperazine administration in rhesus monkeys. , 1984, Life sciences.

[46]  C. Marsden,et al.  Noradrenaline and 5-hydroxytryptamine modulation of brain dopamine function: implications for the treatment of Parkinson's disease. , 1983, British journal of clinical pharmacology.

[47]  R. Kahn,et al.  Behavioral indications for serotonin receptor hypersensitivity in panic disorder , 1988, Psychiatry Research.

[48]  R. Kahn,et al.  Serotonin receptor sensitivity and aggression , 1991, Psychiatry Research.

[49]  D. Murphy,et al.  Neuroendocrine effects of M-chlorophenylpiperazine, a serotonin agonist, in humans. , 1985, The Journal of clinical endocrinology and metabolism.

[50]  D. Murphy,et al.  Serotonin agonists cause parallel activation of the sympathoadrenomedullary system and the hypothalamo-pituitary-adrenocortical axis in conscious rats. , 1989, Endocrinology.

[51]  J. Barrett,et al.  Behavioral studies with anxiolytic drugs. VI. Effects on punished responding of drugs interacting with serotonin receptor subtypes. , 1989, The Journal of pharmacology and experimental therapeutics.

[52]  R. Kahn,et al.  Monoamines and Abnormal Behaviour a Multi-Aminergic Perspective , 1990, British Journal of Psychiatry.

[53]  D. Murphy,et al.  β-Endorphin responses to different serotonin agonists: involvement of corticotropin-releasing hormone, vasopressin and direct pituitary action , 1990, Brain Research.

[54]  R. Fuller,et al.  Antagonism of vascular serotonin receptors by m-chlorophenylpiperazine and m-trifluoromethylphenylpiperazine. , 1983, Life sciences.

[55]  Michel Jouvet,et al.  The raphe nuclei of the cat brain stem: A topographical atlas of their efferent projections as revealed by autoradiography , 1976, Brain Research.

[56]  G Maura,et al.  Cholinergic terminals in rat hippocampus possess 5-HT1B receptors mediating inhibition of acetylcholine release. , 1986, European journal of pharmacology.

[57]  L. Chiodo,et al.  Serotonergic afferent regulation of the basic physiology and pharmacological responsiveness of nigrostriatal dopamine neurons. , 1990, The Journal of pharmacology and experimental therapeutics.

[58]  E. Hollander,et al.  Serotonergic and noradrenergic sensitivity in obsessive-compulsive disorder: behavioral findings. , 1988, The American journal of psychiatry.

[59]  T. Insel,et al.  Serotonergic responsivity in obsessive-compulsive disorder. Comparison of patients and healthy controls. , 1987, Archives of general psychiatry.

[60]  G. Kennett,et al.  Anxiogenic-like effects of mCPP and TFMPP in animal models are opposed by 5-HT1C receptor antagonists. , 1989, European journal of pharmacology.

[61]  H. Fibiger,et al.  An anatomical and electrophysiological investigation of the serotonergic projection from the dorsal raphe nucleus to the substantia nigra in the rat , 1977, Neuroscience.

[62]  N. Munaro.  The effect of ovarian steroids on hypothalamic 5-hydroxytryptamine neuronal activity. , 1978, Neuroendocrinology.

[63]  P. Somogyi,et al.  Neurotransmitter-specific projection neurons revealed by combining PAP immunohistochemistry with retrograde transport of HRP , 1981, Brain Research.

[64]  A. Mørk,et al.  5-Hydroxytryptamine receptor agonists influence calcium-stimulated adenylate cyclase activity in the cerebral cortex and hippocampus of the rat. , 1990, European journal of pharmacology.

[65]  G. Aghajanian,et al.  Relative potencies of alpha-1 and alpha-2 antagonists in the locus ceruleus, dorsal raphe and dorsal lateral geniculate nuclei: an electrophysiological study. , 1982, The Journal of pharmacology and experimental therapeutics.

[66]  E. Coccaro.  Central Serotonin and Impulsive Aggression , 1989, British Journal of Psychiatry.

[67]  R. Kahn,et al.  Hormonal probes of central serotonergic activity: Do they really exist? , 1987, Biological Psychiatry.

[68]  J. Palacios,et al.  Serotonin receptors in the human brain. I. Characterization and autoradiographic localization of 5-HT1A recognition sites. Apparent absence of 5-HT1B recognition sites , 1986, Brain Research.

[69]  G. Mogenson,et al.  Injections of dopaminergic, cholinergic, serotoninergic and gabaergic drugs into the nucleus accumbens: effects on locomotor activity in the rat , 1981, Neuropharmacology.

[70]  D. Murphy,et al.  Effects of daily oral m-Chlorophenylpiperazine in elderly depressed patients initial experience with a serotonin agonist , 1990, Biological Psychiatry.

[71]  D. Murphy,et al.  Different serotonin receptors mediate blood pressure, heart rate, plasma catecholamine and prolactin responses to m-chlorophenylpiperazine in conscious rats. , 1989, The Journal of pharmacology and experimental therapeutics.

[72]  D. Murphy,et al.  Use of serotonergic agents in the clinical assessment of central serotonin function. , 1986, The Journal of clinical psychiatry.

[73]  D. Murphy,et al.  Long-term cortisol treatment impairs behavioral and neuroendocrine responses to 5-HT1 agonists in the rat. , 1989, Neuroendocrinology.

[74]  J. Glowinski,et al.  The topographical distribution of serotoninergic terminals in the neostriatum of the rat and the caudate nucleus of the cat , 1977, Brain Research.

[75]  D. Murphy,et al.  Evidence for a decline with age in behavioral responsivity to the serotonin agonist, m-chlorophenylpiperazine, in healthy human subjects , 1989, Psychiatry Research.

[76]  E. Vizi,et al.  Evidence of the modulatory role of serotonin in acetylcholine release from striatal interneurons , 1981, Brain Research.

[77]  M. B. Tyers,et al.  Pharmacological characterization of 5‐hydroxytryptamine‐induced depolarization of the rat isolated vagus nerve , 1987, British journal of pharmacology.

[78]  G. Chrousos,et al.  Mechanisms of serotonin receptor agonist-induced activation of the hypothalamic-pituitary-adrenal axis in the rat. , 1990, Endocrinology.

[79]  G. Aghajanian,et al.  Suppression of firing activity of 5-HT neurons in the dorsal raphe by alpha-adrenoceptor antagonists , 1980, Neuropharmacology.

[80]  P. Beart,et al.  5‐Hydroxytryptamine and 5‐hydroxytryptaminergic‐dopaminergic interactions in the ventral tegmental area of rat brain , 1982, The Journal of pharmacy and pharmacology.

[81]  I. Lucki,et al.  Effect of 1-(m-chlorophenyl)piperazine and 1-(m-trifluoromethylphenyl)piperazine on locomotor activity. , 1989, The Journal of pharmacology and experimental therapeutics.

[82]  Stanley I. Rapoport,et al.  Time courses of behavioral and regional cerebral metabolic responses to different doses of meta-chlorophenylpiperazine in awake rats , 1990, Brain Research.

[83]  E. Hollander,et al.  Effects of chronic fluoxetine treatment on behavioral and neuroendocrine responses to meta-chloro-phenylpiperazine in obsessive-compulsive disorder , 1991, Psychiatry Research.

[84]  D. Murphy,et al.  Differential neuroendocrine responses to the 5-HT agonist m-chlorophenylpiperazine in Fawn-Hooded rats relative to Wistar and Sprague-Dawley rats. , 1988, Neuroendocrinology.

[85]  K. Drescher,et al.  Influence of antipsychotics on presynaptic receptors modulating the release of dopamine in synaptosomes of the nucleus accumbens of rats , 1986, Neuropharmacology.